Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/25/18
End: 09/30/25
Due: 09/30/26
Phase: N/A
Priority: Normal
Start: 04/12/18
End: 11/30/21
Due: 11/30/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer | NCT03721744 | 1Globe Health Institute LLC | user2@example.com | None | 2018-10-25 | 2025-09-30 | 2026-09-30 | - | - | 2025-07-14 |
| A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer | NCT03522649 | 1Globe Health Institute LLC | user2@example.com | None | 2018-04-12 | 2021-11-30 | 2022-11-30 | - | - | 2025-07-14 |